Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

HSV-1 amplicon vectors launch the production of heterologous rotavirus-like particles and induce rotavirus-specific immune responses in mice.

Laimbacher AS, Esteban LE, Castello AA, Abdusetir Cerfoglio JC, Argüelles MH, Glikmann G, D'Antuono A, Mattion N, Berois M, Arbiza J, Hilbe M, Schraner EM, Seyffert M, Dresch C, Epstein AL, Ackermann M, Fraefel C.

Mol Ther. 2012 Sep;20(9):1810-20. doi: 10.1038/mt.2012.108. Epub 2012 Jun 19.

2.

Transfer of Anti-Rotavirus Antibodies during Pregnancy and in Milk Following Maternal Vaccination with a Herpes Simplex Virus Type-1 Amplicon Vector.

Meier AF, Suter M, Schraner EM, Humbel BM, Tobler K, Ackermann M, Laimbacher AS.

Int J Mol Sci. 2017 Feb 16;18(2). pii: E431. doi: 10.3390/ijms18020431.

3.

Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Lappalainen S, Tamminen K, Vesikari T, Blazevic V.

Hum Vaccin Immunother. 2013 Sep;9(9):1991-2001. doi: 10.4161/hv.25249. Epub 2013 Jun 18.

4.

Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.

Malm M, Heinimäki S, Vesikari T, Blazevic V.

Clin Exp Immunol. 2017 Sep;189(3):331-341. doi: 10.1111/cei.12977. Epub 2017 May 16.

5.

HSV-1 amplicon vectors as genetic vaccines.

Laimbacher AS, Fraefel C.

Methods Mol Biol. 2014;1144:99-115. doi: 10.1007/978-1-4939-0428-0_7.

PMID:
24671679
6.
7.

Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants.

Yang Y, Li X, Yang H, Qian Y, Zhang Y, Fang R, Chen X.

Sci China Life Sci. 2011 Jan;54(1):82-9. doi: 10.1007/s11427-010-4104-3. Epub 2010 Nov 19.

PMID:
21104033
8.

Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.

Lappalainen S, Pastor AR, Malm M, López-Guerrero V, Esquivel-Guadarrama F, Palomares LA, Vesikari T, Blazevic V.

Arch Virol. 2015 Aug;160(8):2075-8. doi: 10.1007/s00705-015-2461-8. Epub 2015 May 29.

9.

Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.

Badillo-Godinez O, Gutierrez-Xicotencatl L, Plett-Torres T, Pedroza-Saavedra A, Gonzalez-Jaimes A, Chihu-Amparan L, Maldonado-Gama M, Espino-Solis G, Bonifaz LC, Esquivel-Guadarrama F.

Vaccine. 2015 Aug 20;33(35):4228-37. doi: 10.1016/j.vaccine.2015.03.080. Epub 2015 Apr 4.

PMID:
25850020
10.

Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana.

Pêra FF, Mutepfa DL, Khan AM, Els JH, Mbewana S, van Dijk AA, Rybicki EP, Hitzeroth II.

Virol J. 2015 Dec 2;12:205. doi: 10.1186/s12985-015-0436-8.

11.

HSV-1 amplicon vectors that direct the in situ production of foot-and-mouth disease virus antigens in mammalian cells can be used for genetic immunization.

D'Antuono A, Laimbacher AS, La Torre J, Tribulatti V, Romanutti C, Zamorano P, Quattrocchi V, Schraner EM, Ackermann M, Fraefel C, Mattion N.

Vaccine. 2010 Oct 28;28(46):7363-72. doi: 10.1016/j.vaccine.2010.09.011. Epub 2010 Sep 17.

PMID:
20851082
12.

Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.

Li T, Lin H, Zhang Y, Li M, Wang D, Che Y, Zhu Y, Li S, Zhang J, Ge S, Zhao Q, Xia N.

Vaccine. 2014 Apr 7;32(17):1921-31. doi: 10.1016/j.vaccine.2014.01.093. Epub 2014 Feb 13.

PMID:
24530406
13.

Chimaeric virus-like particles derived from consensus genome sequences of human rotavirus strains co-circulating in Africa.

Jere KC, O'Neill HG, Potgieter AC, van Dijk AA.

PLoS One. 2014 Sep 30;9(9):e105167. doi: 10.1371/journal.pone.0105167. eCollection 2014.

14.
15.

Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.

Lappalainen S, Pastor AR, Tamminen K, López-Guerrero V, Esquivel-Guadarrama F, Palomares LA, Vesikari T, Blazevic V.

Hum Vaccin Immunother. 2014;10(7):2039-47. doi: 10.4161/hv.28858.

16.

Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.

Blazevic V, Malm M, Arinobu D, Lappalainen S, Vesikari T.

Hum Vaccin Immunother. 2016 Mar 3;12(3):740-8. doi: 10.1080/21645515.2015.1099772.

17.

Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore.

Aiyegbo MS, Sapparapu G, Spiller BW, Eli IM, Williams DR, Kim R, Lee DE, Liu T, Li S, Woods VL Jr, Nannemann DP, Meiler J, Stewart PL, Crowe JE Jr.

PLoS One. 2013 May 9;8(5):e61101. doi: 10.1371/journal.pone.0061101. Print 2013.

18.

Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease.

Azevedo MP, Vlasova AN, Saif LJ.

Expert Rev Vaccines. 2013 Feb;12(2):169-81. doi: 10.1586/erv.13.3. Review.

PMID:
23414408
19.

Intra-peritoneal and intra-rectal immunogenicity induced by rotavirus virus like particles 2/6/7 in mice.

Marashi SM, Jalilvand S, Mollaei-Kandelous Y, Shahmahmoodi S, Rezaei F, Salimi V, Nejati A, Validi M, Shoja Z.

Microb Pathog. 2014 Feb-Mar;67-68:48-54. doi: 10.1016/j.micpath.2014.02.005. Epub 2014 Feb 28.

PMID:
24583154
20.

Supplemental Content

Support Center